Engineering aggregation-resistant antibodies

Annual Review of Chemical and Biomolecular Engineering

Volumn 3, Issue , 2012, Pages 263-286

  Perchiacca, Joseph M ^a   Tessier, Peter M ^a  

^a RENSSELAER POLYTECHNIC INSTITUTE   (United States)

Author keywords

CDR; Complementarity determining region; Fab; IgG; ScFv; Self association; Single chain variable fragment; Solubility; VH

Indexed keywords

CDR; COMPLEMENTARITY-DETERMINING REGIONS; FAB; IGG; SCFV; SELF-ASSOCIATIONS; VARIABLE FRAGMENT; VH;

ASSOCIATION REACTIONS; MONOCLONAL ANTIBODIES; PLANTS (BOTANY);

SOLUBILITY;

ANTIBODY; ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN;

ANIMAL; ANTIBODY SPECIFICITY; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN FOLDING; PROTEIN STABILITY; PROTEIN TERTIARY STRUCTURE; REVIEW; THERMODYNAMICS;

ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; ANTIGENS; BINDING SITES; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN FOLDING; PROTEIN STABILITY; PROTEIN STRUCTURE, TERTIARY; THERMODYNAMICS;

EID: 84862679960     PISSN: 19475438     EISSN: None     Source Type: Journal    
DOI: 10.1146/annurev-chembioeng-062011-081052     Document Type: Review

References (133)

1. Maggon K. 2007. Monoclonal antibody "gold rush." Curr. Med. Chem. 14:1978-87
2. Reichert JM. 2008. Monoclonal antibodies as innovative therapeutics. Curr. Pharm. Biotechnol. 9:423-30
3. Reichert JM, Rosensweig CJ, Faden LB,DewitzMC. 2005. Monoclonal antibody successes in the clinic. Nat. Biotechnol. 23:1073-78
4. Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, et al. 2010. Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol. 28:157-59
5. Hwang WY, Foote J. 2005. Immunogenicity of engineered antibodies. Methods 36:3-10
6. Tan P, Mitchell DA, Buss TN, Holmes MA, Anasetti C, Foote J. 2002. "Superhumanized" antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28. J. Immunol. 169:1119-25
7. Sidhu SS. 2000. Phage display in pharmaceutical biotechnology. Curr. Opin. Biotechnol. 11:610-16
8. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. 1994. Making antibodies by phage display technology. Annu. Rev. Immunol. 12:433-55
9. Boder ET, Wittrup KD. 1997. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 15:553-57
10. Duvall M, Bradley N, Fiorini RN. 2011. A novel platform to produce human monoclonal antibodies: the next generation of therapeutic human monoclonal antibodies discovery. mAbs 3:203-8
11. Bradbury AR, Sidhu S, Dubel S, McCafferty J. 2011. Beyond natural antibodies: the power of in vitro display technologies. Nat. Biotechnol. 29:245-54
12. He M, Khan F. 2005. Ribosome display: next-generation display technologies for production of antibodies in vitro. Expert Rev. Proteomics 2:421-30
13. Yokoyama WM. 2001. Production of monoclonal antibodies. Curr. Protoc. Cell Biol. 161:1-17
14. Loevborg U. 1983. Early screening for hybrid antibodies. Dev. Biol. Stand. 55:173-79
15. Bork P, Holm L, Sander C. 1994. The immunoglobulin fold. Structural classification, sequence patterns and common core. J. Mol. Biol. 242:309-20
16. Ravetch JV, Bolland S. 2001. IgG Fc receptors. Annu. Rev. Immunol. 19:275-90
17. Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G. 1989. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 341:544-46
18. Holliger P, Prospero T, Winter G. 1993. "Diabodies": small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA 90:6444-48
19. Davies J, Riechmann L. 1995. Antibody VH domains as small recognition units. Nat. Biotechnol. 13:475-79
20. Sidhu SS, Li B, Chen Y, Fellouse FA, Eigenbrot C, Fuh G. 2004. Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions. J. Mol. Biol. 338:299-310
21. Pluckthun A, Pack P. 1997. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology 3:83-105
22. Feldhaus MJ, Siegel RW. 2004. Yeast display of antibody fragments: a discovery and characterization platform. J. Immunol. Methods 290:69-80
23. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, et al. 1988. Single-chain antigenbinding proteins. Science 242:423-26
24. Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotny J, et al. 1988. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA 85:5879-83
25. Muyldermans S. 2001. Single domain camel antibodies: current status. J. Biotechnol. 74:277-302
26. Decanniere K, Desmyter A, Lauwereys M, Ghahroudi MA, Muyldermans S, Wyns L. 1999. A singledomain antibody fragment in complex with RNase A: non-canonical loop structures and nanomolar affinity using two CDR loops. Structure 7:361-70
27. Holt LJ, Herring C, Jespers LS, Woolven BP, Tomlinson IM. 2003. Domain antibodies: proteins for therapy. Trends Biotechnol. 21:484-90
28. Holliger P, Hudson PJ. 2005. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23:1126-36
29. Huston JS, McCartney J, Tai MS, Mottola-Hartshorn C, Jin D, et al. 1993. Medical applications of single-chain antibodies. Int. Rev. Immunol. 10:195-217
30. Hudson PJ. 1999. Recombinant antibody constructs in cancer therapy. Curr. Opin. Immunol. 11:548-57
31. Lowe D, Dudgeon K, Rouet R, Schofield P, Jermutus L, Christ D. 2011. Aggregation, stability, and formulation of human antibody therapeutics. Adv. Protein Chem. Struct. Biol. 84:41-61
32. Vazquez-ReyM, Lang DA. 2011. Aggregates in monoclonal antibody manufacturing processes. Biotechnol. Bioeng. 108:1494-508
33. Dani B, Platz R, Tzannis ST. 2007. High concentration formulation feasibility of human immunoglubulin G for subcutaneous administration. J. Pharm. Sci. 96:1504-17
34. Harn N, Allan C, Oliver C, Middaugh CR. 2007. Highly concentrated monoclonal antibody solutions: direct analysis of physical structure and thermal stability. J. Pharm. Sci. 96:532-46
35. He F, Hogan S, Latypov RF,Narhi LO, Razinkov VI. 2010. High throughput thermostability screening of monoclonal antibody formulations. J. Pharm. Sci. 99:1707-20
36. Perico N, Purtell J, Dillon TM, Ricci MS. 2009. Conformational implications of an inversed pHdependent antibody aggregation. J. Pharm. Sci. 98:3031-42
37. Zhang A, Singh SK, Shirts MR, Kumar S, Fernandez EJ. 2012. Distinct aggregation mechanisms of monoclonal antibody under thermal and freeze-thaw stresses revealed by hydrogen exchange. Pharm. Res. 29:236-50
38. Barnard JG, Singh S,RandolphTW,Carpenter JF. 2011. Subvisible particle counting provides a sensitive method of detecting and quantifying aggregation of monoclonal antibody caused by freeze-thawing: insights into the roles of particles in the protein aggregation pathway. J. Pharm. Sci. 100:492-503
39. Serno T, Carpenter JF, Randolph TW, Winter G. 2010. Inhibition of agitation-induced aggregation of an IgG-antibody by hydroxypropyl-β- cyclodextrin. J. Pharm. Sci. 99:1193-206
40. Kiese S, Pappenberger A, FriessW, Mahler HC. 2008. Shaken, not stirred: mechanical stress testing of an IgG1 antibody. J. Pharm. Sci. 97:4347-66
41. Mahler HC, Muller R, Friess W, Delille A, Matheus S. 2005. Induction and analysis of aggregates in a liquid IgG1-antibody formulation. Eur. J. Pharm. Biopharm. 59:407-17
42. Thirumangalathu R, Krishnan S, Ricci MS, Brems DN, Randolph TW, Carpenter JF. 2009. Silicone oil-and agitation-induced aggregation of a monoclonal antibody in aqueous solution. J. Pharm. Sci. 98:3167-81
43. Ejima D, Tsumoto K, Fukada H, Yumioka R, Nagase K, et al. 2007. Effects of acid exposure on the conformation, stability, and aggregation of monoclonal antibodies. Proteins 66:954-62
44. Sahin E, Grillo AO, Perkins MD, Roberts CJ. 2010. Comparative effects of pH and ionic strength on protein-protein interactions, unfolding, and aggregation for IgG1 antibodies. J. Pharm. Sci. 99:4830-48
45. Brummitt RK, Nesta DP, Roberts CJ. 2011. Predicting accelerated aggregation rates for monoclonal antibody formulations, and challenges for low-temperature predictions. J. Pharm. Sci. 100:4234-43
46. Cleland JL, Lam X, Kendrick B, Yang J, Yang TH, et al. 2001. A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody. J. Pharm. Sci. 90:310-21
47. Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W. 2004. Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res. 21:897-903
48. Schellekens H. 2005. Factors influencing the immunogenicity of therapeutic proteins. Nephrol. Dial. Transpl. 20:3-9
49. Roguska MA, Pedersen JT, Keddy CA, Henry AH, Searle SJ, et al. 1994. Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc. Natl. Acad. Sci. USA 91:969-73
50. Carter P, Presta L, Gorman CM, Ridgway JB,HennerD, et al. 1992. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA 89:4285-89
51. Honegger A. 2008. Engineering antibodies for stability and efficient folding. Handb. Exp. Pharmacol. 181:47-68
52. Worn A, Pluckthun A. 2001. Stability engineering of antibody single-chain Fv fragments. J. Mol. Biol. 305:989-1010
53. Paborji M, Pochopin NL, Coppola WP, Bogardus JB. 1994. Chemical and physical stability of chimeric L6, a mouse-human monoclonal antibody. Pharm. Res. 11:764-71
54. Breen ED, Curley JG, Overcashier DE, Hsu CC, Shire SJ. 2001. Effect of moisture on the stability of a lyophilized humanized monoclonal antibody formulation. Pharm. Res. 18:1345-53
55. Pace CN, Shirley BA, Thomson JA. 1997. Measuring the conformational stability of a protein. In Protein Structure: A Practical Approach, ed. T Creighton, pp. 311-30. New York: Oxford Univ. Press. 2nd ed.
56. Bond CJ,Marsters JC, Sidhu SS. 2003. Contributions of CDR3 to VHH domain stability and the design of monobody scaffolds for naive antibody libraries. J. Mol. Biol. 332:643-55
57. Dumoulin M, Conrath K, Van Meirhaeghe A, Meersman F, Heremans K, et al. 2002. Single-domain antibody fragments with high conformational stability. Protein Sci. 11:500-15
58. Saerens D, Pellis M, Loris R, Pardon E, Dumoulin M, et al. 2005. Identification of a universal VHH framework to graft non-canonical antigen-binding loops of camel single-domain antibodies. J. Mol. Biol. 352:597-607
59. Vincke C, Loris R, Saerens D, Martinez-Rodriguez S, Muyldermans S, Conrath K. 2009. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J. Biol. Chem. 284:3273-84
60. Barthelemy PA, Raab H, Appleton BA, Bond CJ, Wu P, et al. 2008. Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains. J. Biol. Chem. 283:3639-54
61. Wirtz P, Steipe B. 1999. Intrabody construction and expression III: engineering hyperstableVH domains. Protein Sci. 8:2245-50
62. Riechmann L. 1996. Rearrangement of the former VL interface in the solution structure of a camelised, single antibody VH domain. J. Mol. Biol. 259:957-69
63. Helms LR, Wetzel R. 1995. Destabilizing loop swaps in the CDRs of an immunoglobulin VL domain. Protein Sci. 4:2073-81
64. Ionescu RM, Vlasak J, Price C, Kirchmeier M. 2008. Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. J. Pharm. Sci. 97:1414-26
65. Perchiacca JM, Bhattacharya M, Tessier PM. 2011. Mutational analysis of domain antibodies reveals aggregation hotspots within and near the complementarity determining regions. Proteins 79:2637-47
66. Desmyter A, Transue TR, Ghahroudi MA, Thi MH, Poortmans F, et al. 1996. Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nat. Struct. Biol. 3:803-11
67. Spinelli S, Frenken L, Bourgeois D, de Ron L, BosW, et al. 1996. The crystal structure of a llama heavy chain variable domain. Nat. Struct. Biol. 3:752-57
68. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, et al. 1993. Naturally occurring antibodies devoid of light chains. Nature 363:446-48
69. Wesolowski J, AlzogarayV,Reyelt J,Unger M, Juarez K, et al. 2009. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med. Microbiol. Immunol. 198:157-74
70. Vu KB, Ghahroudi MA, Wyns L, Muyldermans S. 1997. Comparison of llama VH sequences from conventional and heavy chain antibodies. Mol. Immunol. 34:1121-31
71. Muyldermans S, Atarhouch T, Saldanha J, Barbosa JA, Hamers R. 1994. Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Eng. 7:1129-35
72. JagerM, Pluckthun A. 1999. Domain interactions in antibody Fv and scFv fragments: effects on unfolding kinetics and equilibria. FEBS Lett. 462:307-12
73. Röthlisberger D, Honegger A, Plückthun A. 2005. Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. J. Mol. Biol. 347:773-89
74. Yasui H, Ito W, Kurosawa Y. 1994. Effects of substitutions of amino acids on the thermal stability of the Fv fragments of antibodies. FEBS Lett. 353:143-46
75. Demarest SJ, Glaser SM. 2008. Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr. Opin. Drug Discov. Dev. 11:675-87
76. Reiter Y, Brinkmann U, Webber KO, Jung SH, Lee B, Pastan I. 1994. Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv. Protein Eng. 7:697-704
77. Brinkmann U, Reiter Y, Jung SH, Lee B, Pastan I. 1993. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Proc. Natl. Acad. Sci. USA 90:7538-42
78. Young NM, MacKenzie CR, Narang SA, Oomen RP, Baenziger JE. 1995. Thermal stabilization of a single-chain Fv antibody fragment by introduction of a disulphide bond. FEBS Lett. 377:135-39
79. Zhao JX, Yang L, Gu ZN, Chen HQ, Tian FW, et al. 2010. Stabilization of the single-chain fragment variable by an interdomain disulfide bond and its effect on antibody affinity. Int. J. Mol. Sci. 12:1-11
80. Michaelson JS, Demarest SJ, Miller B, Amatucci A, Snyder WB, et al. 2009. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTßR. mAbs 1:128-41
81. Miller BR, Demarest SJ, Lugovskoy A, Huang F, Wu X, et al. 2010. Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng. Des. Sel. 23:549-57
82. Wang N, SmithWF, Miller BR, Aivazian D, Lugovskoy AA, et al. 2009. Conserved amino acid networks involved in antibody variable domain interactions. Proteins 76:99-114
83. Demarest SJ, ChenG, Kimmel BE, GustafsonD,WuJ, et al. 2006. Engineering stability into Escherichia coli secreted Fabs leads to increased functional expression. Protein Eng. Des. Sel. 19:325-36
84. 3 domain by residue frequency analysis of IgG sequences. J. Mol. Biol. 335:41-48
85. Honegger A, Malebranche AD, Rothlisberger D, Pluckthun A. 2009. The influence of the framework core residues on the biophysical properties of immunoglobulin heavy chain variable domains. Protein Eng. Des. Sel. 22:121-34
86. Ewert S, Honegger A, Pluckthun A. 2003. Structure-based improvement of the biophysical properties of immunoglobulin VH domains with a generalizable approach. Biochemistry 42:1517-28
87. Knappik A, Ge L, Honegger A, Pack P, Fischer M, et al. 2000. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J. Mol. Biol. 296:57-86
88. Monsellier E, Bedouelle H. 2006. Improving the stability of an antibody variable fragment by a combination of knowledge-based approaches: validation and mechanisms. J. Mol. Biol. 362:580-93
89. Ewert S, Huber T, Honegger A, Pluckthun A. 2003. Biophysical properties of human antibody variable domains. J. Mol. Biol. 325:531-53
90. Rowe ES, Tanford C. 1973. Equilibrium and kinetics of the denaturation of a homogeneous human immunoglobulin light chain. Biochemistry 12:4822-27
91. Rowe ES. 1976. Dissociation and denaturation equilibria and kinetics of a homogeneous human immunoglobulin Fab fragment. Biochemistry 15:905-16
92. Perl D, Schmid FX. 2002. Some like it hot: the molecular determinants of protein thermostability. ChemBioChem 3:39-44
93. Becktel WJ, Schellman JA. 1987. Protein stability curves. Biopolymers 26:1859-77
94. Arbabi-Ghahroudi M, Mackenzie R, Tanha J. 2010. Site-directedmutagenesis for improving biophysical properties of VH domains. Methods Mol. Biol. 634:309-30
95. Dudgeon K, Famm K, Christ D. 2009. Sequence determinants of protein aggregation in human VH domains. Protein Eng. Des. Sel. 22:217-20
96. Jespers L, Schon O, James LC, Veprintsev D, Winter G. 2004. Crystal structure of HEL4, a soluble, refoldable human VH single domain with a germ-line scaffold. J. Mol. Biol. 337:893-903
97. Perez JM, Renisio JG, Prompers JJ, van Platerink CJ, Cambillau C, et al. 2001. Thermal unfolding of a llama antibody fragment: a two-state reversible process. Biochemistry 40:74-83
98. 3 domains. Biochemistry 41:3628-36
99. Muyldermans S, Cambillau C, Wyns L. 2001. Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains. Trends Biochem. Sci. 26:230-35
100. Nguyen VK,Hamers R, Wyns L,Muyldermans S. 2000. Camel heavy-chain antibodies: diverse germline VHH and specific mechanisms enlarge the antigen-binding repertoire. EMBO J. 19:921-30
101. Riechmann L,Muyldermans S. 1999. Single domain antibodies: comparison of camel VH and camelised human VH domains. J. Immunol. Methods 231:25-38
102. Davies J, Riechmann L. 1994. "Camelising" human antibody fragments: NMR studies on VH domains. FEBS Lett. 339:285-90
103. Martin F, Volpari C, Steinkuhler C, Dimasi N, Brunetti M, et al. 1997. Affinity selection of a camelized VH domain antibody inhibitor of hepatitis C virus NS3 protease. Protein Eng. 10:607-14
104. Famm K, Hansen L, Christ D, Winter G. 2008. Thermodynamically stable aggregation-resistant antibody domains through directed evolution. J. Mol. Biol. 376:926-31
105. Jespers L, SchonO, Famm K, Winter G. 2004. Aggregation-resistant domain antibodies selected on phage by heat denaturation. Nat. Biotechnol. 22:1161-65
106. Arbabi-Ghahroudi M, To R, Gaudette N, Hirama T, Ding W, et al. 2009. Aggregation-resistant VHs selected by in vitro evolution tend to have disulfide-bonded loops and acidic isoelectric points. Protein Eng. Des. Sel. 22:59-66
107. Shire SJ. 2009. Formulation and manufacturability of biologics. Curr. Opin. Biotechnol. 20:708-14
108. Shire SJ, Shahrokh Z, Liu J. 2004. Challenges in the development of high protein concentration formulations. J. Pharm. Sci. 93:1390-402
109. Wu SJ, Luo J, O'Neil KT, Kang J, Lacy ER, et al. 2010. Structure-based engineering of a monoclonal antibody for improved solubility. Protein Eng. Des. Sel. 23:643-51
110. Pepinsky RB, Silvian L, Berkowitz SA, Farrington G, Lugovskoy A, et al. 2010. Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis. Protein Sci. 19:954-6
111. Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. 2009. Design of therapeutic proteins with enhanced stability. Proc. Natl. Acad. Sci. USA 106:11937-42
112. Wang X, Das TK, Singh SK, Kumar S. 2009. Potential aggregation prone regions in biotherapeutics: a survey of commercial monoclonal antibodies. mAbs 1:254-67
113. Chennamsetty N, Helk B, Voynov V, Kayser V, Trout BL. 2009. Aggregation-prone motifs in human immunoglobulin G. J. Mol. Biol. 391:404-13
114. Kayser V, Chennamsetty N, Voynov V, Forrer K, Helk B, Trout BL. 2011. Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies. Biotechnol. J. 6:38-44
115. Vermeer AW, Norde W. 2000. The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein. Biophys. J. 78:394-404
116. Li Y, Mach H, Blue JT. 2011. High throughput formulation screening for global aggregation behaviors of three monoclonal antibodies. J. Pharm. Sci. 100:2120-35
117. Scherer TM, Liu J, Shire SJ, Minton AP. 2010. Intermolecular interactions of IgG1 monoclonal antibodies at high concentrations characterized by light scattering. J. Phys. Chem. B 114:12948-57
118. Todorovska A, Roovers RC, Dolezal O, Kortt AA, Hoogenboom HR, Hudson PJ. 2001. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J. Immunol. Methods 248:47-66
119. Hudson PJ, Kortt AA. 1999. High avidity scFv multimers; diabodies and triabodies. J. Immunol. Methods 231:177-89
120. Arndt KM, Muller KM, Pluckthun A. 1998. Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment. Biochemistry 37:12918-26
121. Kortt AA, Dolezal O, Power BE, Hudson PJ. 2001. Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomol. Eng. 18:95-108
122. Iliades P, Kortt AA, Hudson PJ. 1997. Triabodies: single chain Fv fragments without a linker form trivalent trimers. FEBS Lett. 409:437-41
123. Atwell JL, Breheney KA, Lawrence LJ, McCoy AJ, Kortt AA, Hudson PJ. 1999. scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies. Protein Eng. 12:597-604
124. Webber KO, Reiter Y, Brinkmann U, Kreitman R, Pastan I. 1995. Preparation and characterization of a disulfide-stabilized Fv fragment of the anti-Tac antibody: comparison with its single-chain analog. Mol. Immunol. 32:249-58
125. Brockmann EC, CooperM, Stromsten N, Vehniainen M, Saviranta P. 2005. Selecting for antibody scFv fragments with improved stability using phage display with denaturation under reducing conditions. J. Immunol. Methods 296:159-70
126. Desmyter A,Decanniere K,Muyldermans S, Wyns L. 2001. Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody. J. Biol. Chem. 276:26285-90
127. Els Conrath K, Lauwereys M, Wyns L, Muyldermans S. 2001. Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J. Biol. Chem. 276:7346-50
128. Wacker M, Linton D, Hitchen PG, Nita-Lazar M, Haslam SM, et al. 2002. N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli. Science 298:1790-93
129. Beck A, Wurch T, Bailly C, Corvaia N. 2010. Strategies and challenges for the next generation of therapeutic antibodies. Nat. Rev. Immunol. 10:345-52
130. Chames P, Baty D. 2009. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? mAbs 1:539-47
131. Chames P, Baty D. 2009. Bispecific antibodies for cancer therapy. Curr. Opin. Drug Discov. Dev. 12:276-83
132. Jordan JL, Arndt JW,Hanf K, LiG,Hall J, et al. 2009. Structural understanding of stabilization patterns in engineered bispecific Ig-like antibody molecules. Proteins 77:832-41
133. Kanai S, Liu J, Patapoff TW, Shire SJ. 2008. Reversible self-association of a concentrated monoclonal antibody solution mediated by Fab-Fab interaction that impacts solution viscosity. J. Pharm. Sci. 97:4219-27